{
  "trade_id": "PASS-2026-008",
  "ticker": "SNY",
  "company": "Sanofi",
  "archetype": "pdufa",
  "decision_date": "2026-01-07",
  "decision": "PASS",
  "reason": "Failed kill screens",

  "event_context": {
    "event_ids": ["EVT-2026-016", "EVT-2026-039"],
    "catalyst": "Multiple FDA decisions (Cerezyme sBLA, Dupixent sBLA)",
    "date": "2026-01-13",
    "days_to_catalyst": 6,
    "note": "Label expansions for existing drugs in a mega-cap pharma."
  },

  "market_data": {
    "price_at_decision": 52.50,
    "market_cap_millions": 117040,
    "note": "Mega-cap ($117B)"
  },

  "kill_screen_results": {
    "passed": false,
    "failures": [
      {
        "screen": "Market Cap Ceiling",
        "threshold_millions": 50000,
        "actual_millions": 117040,
        "status": "FAIL",
        "severity": "critical",
        "note": "Sanofi ($117B) exceeds the $50B cap. Framework targets small/mid-cap inefficiencies. Label expansions in mega-caps typically lack the materiality to drive the idiosyncratic alpha this system seeks."
      }
    ],
    "passes": [
      {
        "screen": "Beneish M-Score",
        "threshold": -1.78,
        "actual": -2.58,
        "status": "PASS"
      },
      {
        "screen": "PDUFA Financial Health",
        "threshold": "Various",
        "actual": "Pass",
        "status": "PASS",
        "note": "Strong cash flow ($11B FCF) and low leverage (0.32 D/E) validate financial health despite borderline Z-Score."
      }
    ]
  },

  "financial_summary": {
    "market_cap_billions": 117.0,
    "z_score": 1.73,
    "m_score": -2.58,
    "cash_position_billions": 10.45
  },

  "thesis_assessment": {
    "bull_case": "Dupixent continues to be a growth engine with new indications (CSU). Cerezyme update removes a legacy overhang. Valuation is reasonable.",
    "bear_case": "Framework violation (Market Cap). The specific catalysts (sBLAs) are incremental, not transformative. Edge in predicting FDA outcomes for mega-caps is low due to high analyst coverage.",
    "framework_view": "Hard pass on size. This is a general pharmaceutical hold, not a special situation trade."
  },

  "lessons_learned": [
    "Mega-caps frequently appear in catalyst calendars (PDUFAs) but rarely fit the 'Special Situation' framework due to size/materiality.",
    "Market Cap Ceiling effectively filters out high-efficiency/low-alpha events."
  ],

  "tags": [
    "pdufa",
    "market_cap_fail",
    "mega_cap",
    "pharma"
  ]
}
